UP FRONT
Pew-Stewart scholars for cancer research.
Five scientists, nominated by leading cancer research institutions, will receive four
years of flexible funding to pursue innovative work aimed at advancing progress
toward a cure for cancer. The 2015 PewStewart scholars for cancer research are:
• Mitchell Guttman, PhD, California
Institute of Technology, Pasadena, CA
• Adam de la Zerda, PhD, Stanford
University, Stanford, CA
• Trever Bivona, MD, PhD, University of
California, San Francisco, CA
• Cigall Kadoch, PhD, Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA
Source: Pew Charitable Trusts press release
• Min Yu, MD, PhD, University of Southern California, Los Angeles, CA
Michael Levy Receives
Lifetime Achievement
Award in Palliative Care
Michael H. Levy, MD, PhD, director of
the Pain and Palliative Care Program at
Fox Chase Cancer Center in Philadelphia,
has received the Lifetime Achievement
Award from the American Academy of
Hospice and Palliative Medicine. The
award recognizes outstanding contribu-
tions and significant
publications that
have helped shape
the direction of the
field of hospice and
palliative medicine.
Dr. Levy has been
at Fox Chase since 1981, where he
developed the Pain and Palliative Care
Program that he currently directs. “My
goal has been, and still is, to carry the
message that hospice and palliative
T:7”
Table 6: Grade 3/4 Adverse Reactions Reported in ≥2% Patients
and With a ≥1% Difference in Proportion of Patients Between the
REVLIMID/dexamethasone and Placebo/dexamethasone groups
System Organ Class/ Preferred Term REVLIMID/Dex# Placebo/Dex#
(N=353)
(N=350)
n (%)
n (%)
Eye Disorders
Cataract
6 (1.7)
1 (0.3)
Cataract Unilateral
5 (1.4)
0 (0.0)
Psychiatric Disorder
Depression
10 (2.8)
6 (1.7)
Venous and Arterial Thromboembolism [see Boxed Warning, Warnings
and Precautions (5.4)]
Deep vein thrombosis (DVT) was reported as a serious (7.4%) or severe
(8.2%) adverse drug reaction at a higher rate in the REVLIMID/dexamethasone
group compared to 3.1 % and 3.4% in the placebo/dexamethasone group,
respectively in the 2 studies in patients with at least 1 prior therapy with
discontinuations due to DVT adverse reactions reported at comparable rates
between groups. In the NDMM study, DVT was reported as an adverse
reaction (all grades: 10.3%, 7.2%, 4.1%), as a serious adverse reaction
(3.6%, 2.0%, 1.7%), and as a Grade 3/4 adverse reaction (5.6%, 3.7%,
2.8%) in the Rd Continuous, Rd18, and MPT Arms, respectively.
Discontinuations and dose reductions due to DVT adverse reactions were
reported at comparable rates between the Rd Continuous and Rd18 Arms
(both <1%). Interruption of REVLIMID treatment due to DVT adverse
reactions was reported at comparable rates between the Rd Continuous
(2.3%) and Rd18 (1.5%) arms.
Pulmonary embolism (PE) was reported as a serious adverse drug reaction
(3.7%) or Grade 3/4 (4.0%) at a higher rate in the REVLIMID/dexamethasone
group compared to 0.9% (serious or grade 3/4) in the p